busulfan has been researched along with Adverse Drug Event in 20 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Complete bioavailability of i." | 6.70 | Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. ( Anderlini, P; Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Gajewski, J; Madden, T; Thall, PF; Tran, HT; Wang, X, 2002) |
| "IVBu is a safe and effective and offers the benefit of predictable and consistent systemic exposure." | 2.75 | Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation. ( Chan, KW; Hayashi, RJ; Kadota, R; Kletzel, M; Mezzi, K; Nieder, ML; Przepiorka, D; Wall, DA; Yeager, AM, 2010) |
| "Complete bioavailability of i." | 2.70 | Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. ( Anderlini, P; Andersson, BS; Champlin, RE; Couriel, D; de Lima, M; Gajewski, J; Madden, T; Thall, PF; Tran, HT; Wang, X, 2002) |
| " In this study, we aimed to investigate the side effect of Bu/Cy and Bu/Flu regimens on our patients who underwent allogeneic bone marrow transplantation." | 1.62 | Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation. ( Hajifathali, A; Mabani, M; Mehdizadeh, M; Parkhideh, S; Rezvani, H; Salari, S, 2021) |
| "Busulfan is a widely used chemotherapeutic drug for chronic myelogenous leukemia and bone marrow transplantation." | 1.51 | Melatonin protects spermatogonia from the stress of chemotherapy and oxidation via eliminating reactive oxidative species. ( Lin, Z; Mi, J; Song, H; Sun, Z; Wei, R; Xia, Q; Yang, Y; Zhang, X; Zou, K, 2019) |
| "For patients with mucopolysaccharidosis type IH (MPS1-H; Hurler syndrome), early allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice." | 1.40 | Unrelated CD3/CD19-depleted peripheral stem cell transplantation for Hurler syndrome. ( Benesch, M; Brunner-Krainz, M; Lackner, H; Paschke, E; Plecko, B; Raicht, A; Schwinger, W; Seidel, M; Sovinz, P; Sperl, D; Strenger, V; Urban, C, 2014) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| " Pharmacokinetic studies were performed after the first dose." | 1.33 | Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. ( Ball, LM; Bredius, RG; Cremers, SC; den Hartigh, J; Egeler, RM; Lankester, AC; Teepe-Twiss, IM; Vossen, JM; Zwaveling, J, 2005) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 9 (45.00) | 24.3611 |
| 2020's | 1 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Mehdizadeh, M | 1 |
| Parkhideh, S | 1 |
| Salari, S | 1 |
| Hajifathali, A | 1 |
| Rezvani, H | 1 |
| Mabani, M | 1 |
| Gholami, M | 1 |
| Abbaszadeh, A | 1 |
| Baharvand, P | 1 |
| Hasanvand, A | 2 |
| Gharravi, AM | 1 |
| Zhang, X | 1 |
| Xia, Q | 1 |
| Wei, R | 1 |
| Song, H | 1 |
| Mi, J | 1 |
| Lin, Z | 1 |
| Yang, Y | 1 |
| Sun, Z | 1 |
| Zou, K | 1 |
| Schwinger, W | 1 |
| Sovinz, P | 1 |
| Benesch, M | 1 |
| Lackner, H | 1 |
| Seidel, M | 1 |
| Strenger, V | 1 |
| Sperl, D | 1 |
| Raicht, A | 1 |
| Brunner-Krainz, M | 1 |
| Paschke, E | 1 |
| Plecko, B | 1 |
| Urban, C | 1 |
| Allewelt, H | 1 |
| El-Khorazaty, J | 1 |
| Mendizabal, A | 1 |
| Taskindoust, M | 1 |
| Martin, PL | 1 |
| Prasad, V | 1 |
| Page, K | 1 |
| Sanders, J | 1 |
| Kurtzberg, J | 1 |
| Wall, DA | 1 |
| Chan, KW | 1 |
| Nieder, ML | 1 |
| Hayashi, RJ | 1 |
| Yeager, AM | 1 |
| Kadota, R | 1 |
| Przepiorka, D | 1 |
| Mezzi, K | 1 |
| Kletzel, M | 1 |
| Andersson, BS | 1 |
| Thall, PF | 1 |
| Madden, T | 1 |
| Couriel, D | 1 |
| Wang, X | 1 |
| Tran, HT | 2 |
| Anderlini, P | 1 |
| de Lima, M | 1 |
| Gajewski, J | 1 |
| Champlin, RE | 1 |
| Fernandez, HF | 1 |
| Albrecht, F | 1 |
| Lennon, S | 1 |
| Caldera, H | 1 |
| Goodman, MS | 1 |
| Zwaveling, J | 1 |
| Bredius, RG | 1 |
| Cremers, SC | 1 |
| Ball, LM | 1 |
| Lankester, AC | 1 |
| Teepe-Twiss, IM | 1 |
| Egeler, RM | 1 |
| den Hartigh, J | 1 |
| Vossen, JM | 1 |
| Bargon, G | 1 |
| Labedzki, L | 1 |
| Noack, D | 1 |
| Westra, WH | 1 |
| Holmes, GF | 1 |
| Eisele, DW | 1 |
| Hussain, S | 1 |
| Saslaw, S | 1 |
| Carlisle, HN | 1 |
| Brettner, A | 1 |
| Heitzman, ER | 1 |
| Woodin, WG | 1 |
2 reviews available for busulfan and Adverse Drug Event
| Article | Year |
|---|---|
[Hematopoietic stimulation for enhanced bone marrow regeneration after chemotherapy (author's transl)].
Topics: Anabolic Agents; Animals; Blood Transfusion; Bone Marrow; Bone Marrow Diseases; Busulfan; Corynebact | 1980 |
Disorders of hemostasis and thrombosis in the aged.
Topics: Adolescent; Adult; Aged; Aortic Aneurysm; Blood Coagulation Disorders; Blood Coagulation Factors; Bl | 1976 |
3 trials available for busulfan and Adverse Drug Event
| Article | Year |
|---|---|
Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Area Under Curve; Busulfan; Child; Child, Preschool; Dose-Response Relationship, Drug; D | 2010 |
Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; | 2002 |
Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Drug Admini | 2002 |
15 other studies available for busulfan and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Adverse Effects of Busulfan Plus Cyclophosphamide versus Busulfan Plus Fludarabine as Conditioning Regimens for Allogeneic Bone Marrow Transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 2021 |
Protective effects of persian honey, Apis Mellifera Meda Skorikov on side effects of chemotherapy and ischemia/reperfusion induced testicular injury.
Topics: Animals; Antineoplastic Agents; Bees; Busulfan; Drug Therapy; Drug-Related Side Effects and Adverse | 2018 |
Melatonin protects spermatogonia from the stress of chemotherapy and oxidation via eliminating reactive oxidative species.
Topics: Animals; Antineoplastic Agents, Alkylating; Antioxidants; Apoptosis; Busulfan; Cells, Cultured; Drug | 2019 |
Unrelated CD3/CD19-depleted peripheral stem cell transplantation for Hurler syndrome.
Topics: Antigens, CD19; Antineoplastic Agents, Alkylating; Busulfan; CD3 Complex; Chimerism; Drug-Related Si | 2014 |
Late Effects after Umbilical Cord Blood Transplantation in Very Young Children after Busulfan-Based, Myeloablative Conditioning.
Topics: Busulfan; Chemically-Induced Disorders; Child, Preschool; Cord Blood Stem Cell Transplantation; Drug | 2016 |
Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity.
Topics: Adolescent; Area Under Curve; Busulfan; Child; Child, Preschool; Drug-Related Side Effects and Adver | 2005 |
[Drug-induced changes in the lungs].
Topics: Albumins; Bleomycin; Busulfan; Carmustine; Drug-Related Side Effects and Adverse Reactions; Humans; | 1984 |
Bizarre epithelial atypia of the sinonasal tract after chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Cell Nucleus; Cyclophosphamide | 2001 |
Nonhuman primates in evaluation of hematotoxicity.
Topics: Animals; Busulfan; Chlorambucil; Cyclophosphamide; Dactinomycin; Drug-Related Side Effects and Adver | 1969 |
Pulmonary complications of drug therapy.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Busulfan; Child; Drug-Related Side Effects and Advers | 1970 |